{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:26:44Z","timestamp":1791163604374,"version":"4.1.0"},"reference-count":115,"publisher":"Oxford University Press (OUP)","issue":"S2","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Non-Hodgkin\u2019s lymphoma (NHL) comprises both indolent forms, including follicular lymphoma (FL) and marginal zone lymphoma (MZL), and aggressive forms, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). FL and DLBCL are the most common subtypes of indolent and aggressive NHL, respectively. Although these lymphomas exhibit different clinical behaviors and outcomes, the prognosis is negatively affected in both DLBCL and FL by the lack of a complete response (CR) with standard treatment options. The aim of therapy should therefore be achievement of a CR, which is not only associated with longer progression-free survival (PFS) and overall survival times, but is also a prerequisite for a cure, particularly in DLBCL.<\/jats:p>\n               <jats:p>Consolidation treatment with radioimmunotherapy (RIT) is an innovative treatment approach to increase CR rates. Phase II studies have indicated promising results with yttrium-90 (90Y)-ibritumomab tiuxetan and iodine-131 (131I)-tositumomab as consolidation following induction therapy for previously untreated patients with advanced FL. More recently, investigators reported a marked increase in CR rates and significant improvements in PFS using standard chemotherapy regimens followed by 90Y-ibritumomab tiuxetan in a phase III randomized trial in patients with previously untreated FL. Data also suggest that RIT may play a role in the treatment of high-risk DLBCL, with encouraging PFS results from a phase II trial of 90Y-ibritumomab tiuxetan consolidation following induction with rituximab plus chemotherapy in elderly patients with previously untreated DLBCL. With the higher CR rates and longer PFS times observed in patients with FL and DLBCL, as well as encouraging early data from MZL and MCL consolidation trials, RIT appears to have an important role in the treatment of patients with NHL.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-s2-17","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T21:40:21Z","timestamp":1255124421000},"page":"17-29","source":"Crossref","is-referenced-by-count":31,"title":["Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin\u2019s Lymphoma: A Review of the Evidence"],"prefix":"10.1093","volume":"14","author":[{"given":"Franck","family":"Morschhauser","sequence":"first","affiliation":[{"name":"H\u00f4pital Claude Huriez, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama","family":"Rohatiner","sequence":"additional","affiliation":[{"name":"St Bartholomew's Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Bischof Delaloye","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"2021122207231843500_R1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/beha.2002.0216","article-title":"Molecular remission and non-Hodgkin\u2019s lymphoma","volume":"15","author":"Darby","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122207231843500_R2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3816\/CLM.2007.n.034","article-title":"Maintenance therapy in lymphoma","volume":"7","author":"Mihelic","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"issue":"suppl 1","key":"2021122207231843500_R3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0145-2126(06)80002-0","article-title":"Principles of maintenance therapy","volume":"30","author":"Berinstein","year":"2006","journal-title":"Leuk Res"},{"key":"2021122207231843500_R4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/CCO.0b013e3282c9ad65","article-title":"Maintenance therapy for low-grade lymphomas: Has the time come?","volume":"19","author":"Cartron","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"2021122207231843500_R5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.beha.2007.11.004","article-title":"Consolidation therapy: What should be the standard of care?","volume":"21","author":"Rowe","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122207231843500_R6","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"key":"2021122207231843500_R7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/annonc\/mdm520","article-title":"Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trial LNH98\u2013B2","volume":"19","author":"Morel","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207231843500_R8","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"2021122207231843500_R9","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1182\/blood.V83.12.3800.3800","article-title":"Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow","volume":"83","author":"Gribben","year":"1994","journal-title":"Blood"},{"key":"2021122207231843500_R10","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"2021122207231843500_R11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.hoc.2008.07.011","article-title":"Marginal zone lymphomas","volume":"22","author":"Zucca","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122207231843500_R12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"2021122207231843500_R13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122207231843500_R14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.2009-S2-4","article-title":"Harnessing the energy: Development of radioimmunotherapy for patients with non-Hodgkin\u2019s lymphoma","volume":"14","author":"Gregory","year":"2009","journal-title":"The Oncologist"},{"issue":"suppl 17","key":"2021122207231843500_R15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminoncol.2003.10.004","article-title":"Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin)","volume":"30","author":"Gregory","year":"2003","journal-title":"Semin Oncol"},{"key":"2021122207231843500_R16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"2021122207231843500_R17","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.1999.17.8.2499","article-title":"Low-grade stage III-IV follicular lymphoma: Multivariate analysis of prognostic factors in 484 patients\u2014a study of the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"17","author":"Decaudin","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R18","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"2021122207231843500_R19","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122207231843500_R20","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/annonc\/8.suppl_2.S11","article-title":"Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group)","volume":"8","author":"Harris","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122207231843500_R21","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","article-title":"Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122207231843500_R22","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: Prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R23","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R24","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1080\/10428190701606867","article-title":"Current treatment options in follicular lymphoma: Science and bias","volume":"48","author":"Emmanouilides","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2021122207231843500_R25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2590.2590","article-title":"Long term follow-up of the GELF86 French and Belgian trials: Complete remission after first line treatment with conventional chemotherapy in newly diagnosed follicular lymphoma patients correlates with prolonged overall survival compared with partial remission [abstract 2590]","volume":"112","author":"Bachy","year":"2008","journal-title":"Blood"},{"key":"2021122207231843500_R26","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R28","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"2021122207231843500_R29","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R30","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":"Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma","volume":"22","author":"Zinzani","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10428190701784714","article-title":"Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma","volume":"49","author":"Economopoulos","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122207231843500_R32","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"2021122207231843500_R33","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"2021122207231843500_R34","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R35","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"2021122207231843500_R36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R37","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/1097-0142(197912)44:6<1983::AID-CNCR2820440604>3.0.CO;2-4","article-title":"Nodular malignant lymphomas: Factors affecting complete response rate and survival","volume":"44","author":"Cabanillas","year":"1979","journal-title":"Cancer"},{"key":"2021122207231843500_R38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/10428199609045721","article-title":"Prolonged survival in follicular non Hodgkins lymphoma is predicted by achievement of complete remission with initial treatment: Results of a long-term study with multivariate analysis of prognostic factors","volume":"24","author":"Davidge-Pitts","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"2021122207231843500_R39","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"2021122207231843500_R40","doi-asserted-by":"crossref","first-page":"147a","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): Survival analyses with extended follow-up (F\/Up) of 7 years [abstract 486]","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"key":"2021122207231843500_R41","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.10894","article-title":"Rituximab maintenance therapy: A step forward in follicular lymphoma","volume":"92","author":"van Oers","year":"2007","journal-title":"Haematologica"},{"key":"2021122207231843500_R42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1053\/beha.2002.0221","article-title":"High-dose treatment with autologous haemopoietic progenitor cell support for large B-cell, follicular and mantle-cell lymphoma","volume":"15","author":"Rohatiner","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122207231843500_R43","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","article-title":"The clinical significance of molecular response in indolent follicular lymphomas","volume":"91","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Blood"},{"key":"2021122207231843500_R44","first-page":"iv180","article-title":"Prognostic significance of molecular remission in follicular lymphoma and impact of consolidation treatment [abstract 326]","volume":"19","author":"Pott","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207231843500_R45","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122207231843500_R46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1634\/theoncologist.2009-S2-41","article-title":"Radioimmunotherapy for stem cell transplantation in non-Hodgkin\u2019s lymphoma: In pursuit of a complete response","volume":"14","author":"Gisselbrecht","year":"2009","journal-title":"The Oncologist"},{"key":"2021122207231843500_R47","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"2021122207231843500_R48","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"2021122207231843500_R49","doi-asserted-by":"crossref","volume-title":"Autologous stem cell transplantation after myeloablative therapy in first remission may be beneficial in patients with advanced stage follicular lymphoma after front-line therapy with R-CHOP. An analysis of two consecutive studies of the German Low Grade Lymphoma Study Group (GLSG) [abstract 772]","author":"Hiddemann","DOI":"10.1182\/blood.V112.11.772.772"},{"key":"2021122207231843500_R50","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R51","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","article-title":"Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group","volume":"22","author":"Lenz","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R52","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2006.10.5957","article-title":"Lymphoma in older patients","volume":"25","author":"Thieblemont","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R53","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"2021122207231843500_R54","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin\u2019s lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R55","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R56","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R57","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"2021122207231843500_R58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","article-title":"Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin\u2019s lymphoma","volume":"23","author":"Vose","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R59","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","article-title":"Dose-fractionated radioimmunotherapy in non-Hodgkin\u2019s lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab","volume":"11","author":"Lind\u00e9n","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122207231843500_R60","doi-asserted-by":"crossref","first-page":"454s","DOI":"10.1200\/jco.2008.26.15_suppl.8502","article-title":"Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y [abstract 8502]","volume":"26","author":"Kraeber-Bodere","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R61","volume-title":"Fractionated radioimmunotherapy in NHL with dota-conjugated, humanized anti-CD22 epratuzumab at high cumulative 90Y doses [abstract 0409]","author":"Morschhauser"},{"key":"2021122207231843500_R62","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin\u2019s lymphoma","volume":"47","author":"Emmanouilides","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2021122207231843500_R63","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122207231843500_R64","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cncr.23236","article-title":"A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma","volume":"112","author":"Zinzani","year":"2008","journal-title":"Cancer"},{"key":"2021122207231843500_R65","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"key":"2021122207231843500_R66","doi-asserted-by":"crossref","first-page":"409a","DOI":"10.1182\/blood.V110.11.1360.1360","article-title":"A prospective study evaluating the safety and efficacy of combination therapy with fludarabine plus mitoxantrone followed by yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) and maintenance rituximab as front line therapy for patients with intermediate or high risk follicular non-Hodgkin\u2019s lymphoma [abstract 1360]","volume":"110","author":"Gregory","year":"2007","journal-title":"Blood"},{"key":"2021122207231843500_R67","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122207231843500_R68","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V112.11.3056.3056","article-title":"R-FND followed by radioimmunotherapy for high-risk follicular lymphoma [abstract 3056]","volume":"112","author":"McLaughlin","year":"2008","journal-title":"Blood"},{"key":"2021122207231843500_R69","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R70","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14 suppl","key":"2021122207231843500_R71","first-page":"562","article-title":"Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin\u2019s lymphoma (NHL) [abstract 6520]","volume":"22","author":"Link","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R72","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.47.43","article-title":"Radioimmunotherapy for non-Hodgkin lymphoma: Historical perspective and current status","volume":"47","author":"Emmanouilides","year":"2007","journal-title":"J Clin Exp Hematop"},{"key":"2021122207231843500_R74","first-page":"354","article-title":"A practical methodology for patient release after tositumomab and 131I-tositumomab therapy","volume":"43","author":"Siegel","year":"2002","journal-title":"J Nucl Med"},{"key":"2021122207231843500_R75","first-page":"1230","article-title":"Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy","volume":"39","author":"Gates","year":"1998","journal-title":"J Nucl Med"},{"issue":"16 suppl","key":"2021122207231843500_R76","first-page":"579s","article-title":"Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial [abstract 6577]","volume":"23","author":"Shipley","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R77","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","article-title":"Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: A phase II non-randomised trial (FLUMIZ)","volume":"9","author":"Zinzani","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021122207231843500_R78","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1200\/JCO.2008.18.5447","article-title":"Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas","volume":"26","author":"Press","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R79","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","article-title":"Phase 1\/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy","volume":"113","author":"Illidge","year":"2009","journal-title":"Blood"},{"key":"2021122207231843500_R80","doi-asserted-by":"crossref","first-page":"999A","DOI":"10.1182\/blood.V110.11.3412.3412","article-title":"Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin\u00ae) as consolidation of first remission in patients with advanced stage follicular lymphoma: A \u2018real-time\u2019 MBR RQ-PCR analysis [abstract 3412]","volume":"110","author":"Goff","year":"2007","journal-title":"Blood"},{"key":"2021122207231843500_R81","doi-asserted-by":"crossref","first-page":"1000A","DOI":"10.1182\/blood.V110.11.3415.3415","article-title":"Dosimetric analysis of 90Y-ibritumomab tiuxetan (Zevalin\u00ae) given as consolidation of first remission in patients with advanced-stage follicular lymphoma in the international Phase 3 First-line Indolent Trial (FIT) [abstract 3415]","volume":"110","author":"Bischof-Delaloye","year":"2007","journal-title":"Blood"},{"key":"2021122207231843500_R82","doi-asserted-by":"crossref","first-page":"974A","DOI":"10.1182\/blood.V110.11.3319.3319","article-title":"Health-related quality of life in patients with advanced-stage follicular lymphoma receiving consolidation with 90Y-ibritumomab tiuxetan (Zevalin\u00ae) of first remission: Results from the randomized phase 3 First-line Indolent Trial (FIT) [abstract 3319]","volume":"110","author":"Gondek","year":"2007","journal-title":"Blood"},{"key":"2021122207231843500_R83","volume-title":"European Medicines Agency. Committee for Medicinal Products for Human Use Post-authorisation Summary of Positive Opinion for Zevalin"},{"key":"2021122207231843500_R84","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/cncr.22066","article-title":"Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma","volume":"107","author":"Weigert","year":"2006","journal-title":"Cancer"},{"key":"2021122207231843500_R85","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejca.2007.12.008","article-title":"Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice\u2014report of a European workshop","volume":"44","author":"Zinzani","year":"2008","journal-title":"Eur J Cancer"},{"key":"2021122207231843500_R86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","article-title":"Results of a national consensus workshop: Therapeutic algorithm in patients with follicular lymphoma\u2014role of radioimmunotherapy","volume":"86","author":"Dreyling","year":"2007","journal-title":"Ann Hematol"},{"key":"2021122207231843500_R87","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V112.11.3061.3061","article-title":"90Y ibritumomab tiuxetan as initial treatment for follicular lymphoma (ZEUS Protocol). An Italian Cooperative Study Group [abstract 3061]","volume":"112","author":"Carella","year":"2008","journal-title":"Blood"},{"key":"2021122207231843500_R88","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1080\/10428190701636468","article-title":"The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the rituximab era","volume":"48","author":"Wirth","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2021122207231843500_R89","doi-asserted-by":"crossref","first-page":"9A","DOI":"10.1182\/blood.V106.11.15.15","article-title":"No role for chemoradiotherapy when compared with chemotherapy alone in elderly patients with localized low risk aggressive lymphoma: Final results of the LNH93\u20134 GELA study [abstract 15]","volume":"106","author":"Fillet","year":"2005","journal-title":"Blood"},{"key":"2021122207231843500_R90","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMoa042040","article-title":"; Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma","volume":"352","author":"Reyes","year":"2005","journal-title":"N Engl J Med"},{"issue":"18 suppl","key":"2021122207231843500_R91","first-page":"443s","article-title":"Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients [abstract 8009]","volume":"25","author":"Coiffier","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R92","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/10428190701882187","article-title":"Current treatment approaches for diffuse large B-cell lymphoma","volume":"49","author":"Illidge","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122207231843500_R93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"2021122207231843500_R94","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021122207231843500_R95","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R96","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.bmt.1705744","article-title":"Autotransplant conditioning regimens for aggressive lymphoma: Are we on the right road?","volume":"40","author":"Fernandez","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2021122207231843500_R97","first-page":"26","article-title":"Treatment of aggressive non-Hodgkin\u2019s lymphoma: A north American perspective","volume":"19","author":"Sehn","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"2021122207231843500_R98","doi-asserted-by":"crossref","first-page":"499A","DOI":"10.1182\/blood.V110.11.1673.1673","article-title":"Second cancers after autologous hematopoietic stem cell transplantation (ASCT) for relapsed\/refractory aggressive non-Hodgkin\u2019s lymphoma (NHL) [abstract 1673]","volume":"110","author":"Seshadri","year":"2007","journal-title":"Blood"},{"key":"2021122207231843500_R99","first-page":"1481","article-title":"Risk of second cancer after treatment of aggressive non-Hodgkin\u2019s lymphoma: An EORTC cohort study","volume":"91","author":"Moser","year":"2006","journal-title":"Haematologica"},{"key":"2021122207231843500_R100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"key":"2021122207231843500_R101","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"key":"2021122207231843500_R102","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"2021122207231843500_R103","doi-asserted-by":"crossref","first-page":"146A","DOI":"10.1182\/blood.V106.11.487.487","article-title":"A phase II study of myeloablative I-131-anti CD-20 (tositumomab) radioimmunotherapy and autologous hematopoietic stem cell transplantation (ASCT) for adults &gt;60 years of age with high-risk relapsed or refractory B-cell lymphoma [abstract 487]","volume":"106","author":"Gopal","year":"2005","journal-title":"Blood"},{"issue":"18 suppl","key":"2021122207231843500_R104","first-page":"444s","article-title":"Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation [abstract 8013]","volume":"25","author":"Vose","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207231843500_R105","doi-asserted-by":"crossref","first-page":"190B","DOI":"10.1182\/blood.V110.11.4478.4478","article-title":"Radioimmunotherapy (RIT) with 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of relapsed or resistant aggressive diffuse large B-cell lymphoma (DLBCL) heavily pretreated with rituximab + chemotherapy: A GIMURELL experience [abstract 4478]","volume":"110","author":"Botto","year":"2007","journal-title":"Blood"},{"issue":"suppl 4","key":"2021122207231843500_R106","first-page":"iv100","article-title":"Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL [abstract 054]","volume":"19","author":"Hamlin","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207231843500_R107","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma","volume":"142","author":"Jares","year":"2008","journal-title":"Br J Haematol"},{"key":"2021122207231843500_R108","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00001622-200109000-00005","article-title":"Biology and management of mantle cell lymphoma","volume":"13","author":"Leonard","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"2021122207231843500_R109","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"2021122207231843500_R110","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122207231843500_R111","doi-asserted-by":"crossref","first-page":"277B","DOI":"10.1182\/blood.V106.11.4786.4786","article-title":"Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) in patients with relapsed or refractory mantle cell lymphoma (MCL) after\/not appropriate for autologous stem cell transplantation (ASCT)\u2014a phase II trial of the European MCL network [abstract 4786]","volume":"106","author":"Weigert","year":"2005","journal-title":"Blood"},{"key":"2021122207231843500_R112","first-page":"767A","article-title":"Phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) in patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract 2714]","volume":"108","author":"Wang","year":"2006","journal-title":"Blood"},{"key":"2021122207231843500_R113","doi-asserted-by":"crossref","first-page":"436A","DOI":"10.1200\/jco.2006.24.18_suppl.7560","article-title":"Sequential radioimmunotherapy with tositumomab\/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract 7560]","volume":"24","author":"Zelenetz","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021122207231843500_R114","first-page":"iv173","article-title":"Radioimmunotherapy (RIT) as an alternative consolidation of MCL patients not eligible for transplant protocols\u2014final analysis of multicenter Polish Lymphoma Research Group (PLRG) trial with 90Y-Zevalin (90Y-ibritumomab tiuxetan) [abstract 303]","volume":"19","author":"Jurczak","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207231843500_R115","doi-asserted-by":"crossref","first-page":"121A","DOI":"10.1182\/blood.V110.11.389.389","article-title":"Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499 [abstract 389]","volume":"110","author":"Smith","year":"2007","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-S2-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-S2-17","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/S2\/17\/41841611\/oncolo_14_s2_17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/S2\/17\/41841611\/oncolo_14_s2_17.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:56:34Z","timestamp":1640159794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/S2\/17\/6398778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,1]]},"references-count":115,"journal-issue":{"issue":"S2","published-online":{"date-parts":[[2009,10,1]]},"published-print":{"date-parts":[[2009,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-s2-17","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,10,1]]},"published":{"date-parts":[[2009,10,1]]}}}